The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Pediatric Rheumatology Research Highlights Successful Approaches to Manage Juvenile Rheumatic Diseases

Pediatric Rheumatology Research Highlights Successful Approaches to Manage Juvenile Rheumatic Diseases

February 15, 2017 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Using data from the Research Registry for Neonatal Lupus, the researchers analyzed questionnaire data and DNA mapping of 346 children exposed to anti-Ro in utero, including 134 with cardiac NL and 74 with cutaneous NL, and 138 of their unaffected siblings. Sixty-three percent of the subjects’ mothers had either Sjögren’s syndrome or systemic lupus erythematosus, said Dr. Garza.

You Might Also Like
  • Pediatric Rheumatologist Shortage Spurs Need for Adult Specialists to Treat Children with Rheumatic Conditions
  • Growing Up Confident with Juvenile Idiopathic Arthritis
  • Quality Measures Used to Assess Care, Improve Outcomes in Children, Adults with Rheumatic Diseases
Explore This Issue
February 2017
Also By This Author
  • New Tools for Myositis Diagnosis, Classification & Management

They found that 15 of the cardiac NL and two of the cutaneous NL patients developed autoimmune diseases later, with psoriasis most prevalent. Five out of 138 siblings unaffected by NL developed other autoimmune diseases later, he said. Psoriasis gene regions were significant in cardiac NL patients.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Geographic Disparities

JIA patients exhibit different disease outcomes depending on where they live, possibly due to availability of biologics in wealthier countries, according to a new study of 8,779 patients conducted by Prof. Angelo Ravelli and his research group at Istituto Giannina Gaslini in Genova, Italy.6

“We wanted to define and compare epidemiology of different JIA categories in different geographic areas, and to compare treatments used in different pediatric rheumatology centers, including the availability of biologics, and to compare outcomes across the world,” said Alessandro Consolaro, MD, PhD, a lead author of the study.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

[In focus groups,] adolescents identified activity & participation, & the psychosocial impact of disease as important domains. Young adults most frequently cited psychosocial impact.

The researchers analyzed questionnaires from JIA patients and parents in the Epidemiology, Treatment and Outcome of Childhood Arthritis (EPOCA) study, including data from 53 countries and 130 pediatric rheumatology centers from the Pediatric Rheumatology International Trials Organization (PRINTO).

Fifty percent of JIA patients in North America received one or more biologics, and patients in Southeast Asia reported the lowest frequency of biologic use, said Dr. Consolaro. Biologics were less frequently used in regions with lower GDPs, he said.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

JIA patients in North Africa/Middle East and Eastern Europe reported higher disease activity scores based on cJADAS-10, and patients in Western Europe, North America and Southeast Asia had low scores. The study’s results showed a modest negative correlation between disease outcome and regions’ GDPs, he said.


Susan Bernstein is a freelance medical journalist based in Atlanta.

References

  1. Walter M, Kamphuis SSM, van Pelt PA, et al. Evaluation of a clinical transition pathway for adolescents with autoimmune diseases (abstract). Arthritis Rheumatol. 2016;68 (suppl 10).
  2. Risum K, Edvardsen E, Selvaag AM, et al. Cardiorespiratory fitness in children with juvenile idiopathic arthritis treated in the biological era is comparable with controls: A cross-sectional study (abstract). Arthritis Rheumatol. 2016;68 (suppl 10).
  3. Horonjeff JR, Thornhill S, Horton DB, et al. Reconsidering the juvenile idiopathic arthritis core set: How patients and caregivers define disease activity (abstract). Arthritis Rheumatol. 2016;68 (suppl 10).
  4. Giancane G, Swart J, Bovis F. Risk of infections in juvenile idiopathic arthritis patients treated with biologic agents and/or methotrexate: Results from pharmachild registry (abstract). Arthritis Rheumatol. 2016;68 (suppl 10).
  5. Garza Romero A, Izmirly PM, Ainsworth HC, et al. Development of autoimmune diseases and genetic predisposition in children with neonatal lupus and their unaffected siblings (abstract). Arthritis Rheumatol. 2016;68 (suppl 10).
  6. Consolaro A, Ruperto N, van Dijkhuizen P, et al. Differences in disease phenotype, management and outcomes of children with juvenile idiopathic arthritis throughout the world—Analysis of 8,325 patients enrolled in the EPOCA study (abstract). Arthritis Rheumatol. 2016;68 (suppl 10).

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Meeting Reports Tagged With: 2016 ACR/ARHP Annual Meeting, Juvenile idiopathic arthritis, Management, outcome, patient care, Pediatric, rheumatologist, rheumatology, TreatmentIssue: February 2017

You Might Also Like:
  • Pediatric Rheumatologist Shortage Spurs Need for Adult Specialists to Treat Children with Rheumatic Conditions
  • Growing Up Confident with Juvenile Idiopathic Arthritis
  • Quality Measures Used to Assess Care, Improve Outcomes in Children, Adults with Rheumatic Diseases
  • The ACR Participates in Workgroup to Aid Transition of Pediatric Patients to Adult Healthcare Settings

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)